# GPT 5.2 Review - Round 5/10

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-19T23:53:09.352894
**Response ID:** resp_06b71ad04eac375200696eb4c3914881969c5f3aa25a738d72
**Tokens:** 9812 in / 9498 out
**Response SHA256:** 575d55057a7c8878

---

## Referee Report: “Hot Standards, Cool Workers? The Effect of State Heat Illness Prevention Regulations on Workplace Injuries” (Jan 2026)

### Summary
The paper studies whether state heat-illness prevention standards (water/rest/shade, training, plans) reduce workplace injuries in outdoor industries. It uses staggered adoption across states and a DiD design, with Callaway & Sant’Anna (2021) as the main estimator. The headline estimate is a reduction of ~7.1 injuries per 10,000 FTE (≈12%). The topic is important and timely (OSHA federal proposal 2024), and the author is clearly aiming to follow modern DiD practice.

However, as currently written, there are serious internal inconsistencies in the policy timing/sample, plus thin identifying variation (effectively only the 2022–2023 adopters within the stated sample window), which substantially undermines credibility. I do **not** think the paper is currently publishable in a top general-interest journal or AEJ:EP without a major redesign of the empirical setup and clearer data/policy construction.

---

# 1. FORMAT CHECK

### Length
- The manuscript excerpt is **~18 pages** including references/figures (page numbers run to 18). This is **below the 25-page minimum** you asked for, and far below typical AER/QJE/JPE/ReStud lengths for policy evaluation papers. Even for AEJ:EP, the main text is typically >25 pages plus appendix.

### References
- The bibliography covers core DiD methodology (Callaway–Sant’Anna; Sun–Abraham; Goodman-Bacon; de Chaisemartin–D’Haultfoeuille; Bertrand–Duflo–Mullainathan; Borusyak–Jaravel–Spiess) and some OSHA enforcement classics (Viscusi; Gray–Scholz; Levine et al.).
- The **domain literature on heat exposure and occupational injuries/illnesses is thin** and reads more like a placeholder than a comprehensive positioning (Section 2). You need substantially more engagement with occupational health/epidemiology evidence, and with economics work linking heat to injuries (not just productivity/mortality).

### Prose vs bullets
- Major sections are written in paragraphs (good). No bullet-point dependence in the Introduction/Results/Discussion.

### Section depth
- Introduction (Section 1) has multiple substantive paragraphs (good).
- Literature (Section 2) is short but in paragraphs; it is borderline for “3+ substantive paragraphs per subsection,” especially for the domain portion.
- Results/robustness sections exist but are **not yet deep enough** for top journals: e.g., the heterogeneity section is very thin and contains factual errors (details below).

### Figures
- Figure 1 and Figure 2 have labeled axes and visible data. Titles/notes are present.
- But Figure 1’s notes/legend are internally inconsistent (see Identification/Policy construction issues).

### Tables
- Tables contain real numbers with SEs and Ns (good).
- But Table 4 appears to contain **incorrect state assignments** (AZ listed as “treated”) and contradictory definitions (“bottom tercile” for “hot”).

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- PASS: Key coefficients in Tables 3–6 include SEs in parentheses.

### (b) Significance testing
- PASS: Significance stars and/or CIs are reported.

### (c) Confidence intervals
- PASS: Table 3 reports 95% CIs for the main estimate; the abstract also reports a CI.

### (d) Sample sizes
- PASS: N is reported (e.g., Table 3, 686).

### (e) DiD with staggered adoption
- Conditional PASS: You use Callaway & Sant’Anna as the main estimator and present Sun–Abraham as an alternative; TWFE is clearly labeled and discussed as potentially attenuated. This is the right direction.

**But**: the application of these estimators appears inconsistent with your stated sample window and adoption timing (e.g., treated cohorts with no post-period; early-treated cohort with no pre-period). These are not mere presentation issues: they change what is identified.

### (f) RDD
- Not applicable.

### Inference concerns that remain (even though you “pass” the checklist)
1. **Few treated cohorts / effective treated variation**: With the stated 2010–2023 sample (Section 4.3), only Oregon (2022) and Washington (2023) have meaningful post periods; Maryland (2024) has none; California (2005) is always-treated with no pre. Conventional cluster-robust inference may be misleading when “effective treatment variation” is this limited. Top journals will expect randomization inference / placebo-law inference, or Conley–Taber-style inference, or at least wild cluster bootstrap carefully justified.
2. **Bootstrap iterations**: 500 multiplier bootstrap reps is light for publication-grade inference, especially with high leverage cohorts and few treated groups. Increase to ≥1,999 (and show stability).

Bottom line: **your inference reporting is present, but the design structure makes the reported precision hard to believe without stronger justification and alternative inference.**

---

# 3. IDENTIFICATION STRATEGY

### Core problem: policy timing + sample window inconsistencies (major)
There are several contradictions that must be resolved before identification can be assessed:

1. **Sample ends in 2023 (Section 4.3), but Maryland is treated in 2024 and still appears as a treated cohort throughout.**
   - If Maryland is included as “ever-treated” with \(G=2024\), then within 2010–2023 it is *not-yet-treated* only. It should not contribute to post-treatment ATT, event-study post coefficients, or “currently treated” shares as stated.
   - Yet Figure 1’s legend includes “Maryland (2024)” and plots a line through 2023, and Table 3 says “Treated states 4.”

2. **California adopted in 2005 but your panel starts in 2010.**
   - You claim “up to 18 years of post-treatment data for California” (Section 4.3), but 2010–2023 provides **14** years total and **zero pre-treatment** years for CA.
   - A DiD design **cannot identify CA’s effect** without pre-treatment outcomes (unless you use pre-2005 data, or a different design like synthetic control using earlier years).
   - If CA is included in the CS estimator, you must explain exactly how the estimator is implemented with an always-treated unit relative to the panel start. Many implementations will drop such cohorts or treat them differently. As written, it’s unclear and potentially invalid.

3. **Colorado is excluded from the main sample (Table 1 notes), but Figure 1 annotates “OR/CO adopt” and the note says “Oregon and Colorado adopted in 2022.”**
   - This is confusing about what is treated in the main estimates and what is merely descriptive.

4. **Heterogeneity table errors (Table 4).**
   - Table 4’s note says “Hot climate states: CA, AZ (among treated).” **Arizona is not treated** in your policy table.
   - It also defines hot climate as the “bottom tercile” of summer temperature, which is directionally wrong (bottom tercile is cooler).

These are not cosmetic issues; they undermine trust in the core research design.

### Parallel trends / pretrends
- Figure 2 shows pre-treatment coefficients near zero for event times -4 to -1. That is helpful, but the window is short and the number of cohorts contributing is tiny.
- A top journal will want:
  - cohort-specific pretrends,
  - joint pretrend tests reported clearly,
  - sensitivity analysis to violations of parallel trends (e.g., “honest DiD”).

### Confounding and alternative mechanisms
Even if timing issues are fixed, the identifying assumption is not yet defended adequately:

- **Heat standards are plausibly adopted following extreme heat events** (you mention the 2021 heat dome). That can violate parallel trends if heat events shift underlying injury risk differentially in treated states right around adoption.
- You need a clear plan for separating “policy effect” from “heat shock effect”:
  - incorporate weather controls (e.g., heat index exceedance days) or
  - a triple-difference design interacting treatment with realized heat exposure.
- COVID sensitivity (dropping 2020–2021) is a good start, but not sufficient given contemporaneous shocks in 2022–2023 (labor market tightness, composition changes, reporting changes, wildfire smoke rules in some states, etc.).

### Placebos / robustness
- Manufacturing placebo (Table 5) is a reasonable negative control, though manufacturing is not a perfect “unexposed” sector (warehousing/manufacturing can have heat exposure).
- Robustness including MN/CO is informative, but the design should ideally exploit **industry-by-state** variation: Colorado’s agriculture-only rule is not a reason to drop the state; it is an opportunity for a sharper test (agriculture should move; construction should not).

### Conclusions vs evidence
- The paper’s policy extrapolation (“tens of thousands” prevented) is premature given:
  - very limited treated cohorts in the effective sample,
  - unclear contribution of CA (no pre),
  - possible confounding by heat shocks driving both adoption and injuries.

---

# 4. LITERATURE (missing references + BibTeX)

### Methodology references you should add (important)
You cite Roth (2022) but you do not implement the modern sensitivity approach. Top journals will expect you to engage with and/or apply these:

1) **Honest DiD / sensitivity to parallel trends**
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

2) **Inference with few treated groups / policy variation**
```bibtex
@article{ConleyTaber2011,
  author  = {Conley, Timothy G. and Taber, Christopher R.},
  title   = {Inference with {``Difference in Differences''} with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year    = {2011},
  volume  = {93},
  number  = {1},
  pages   = {113--125}
}
```

3) **Stacked DiD as a design choice (especially with late adopters)**
```bibtex
@article{CengizEtAl2019,
  author  = {Cengiz, Doruk and Dube, Arindrajit and Lindner, Attila and Zipperer, Ben},
  title   = {The Effect of Minimum Wages on Low-Wage Jobs},
  journal = {Quarterly Journal of Economics},
  year    = {2019},
  volume  = {134},
  number  = {3},
  pages   = {1405--1454}
}
```

4) **Wild cluster bootstrap (common in policy DiD)**
```bibtex
@article{MacKinnonWebb2017,
  author  = {MacKinnon, James G. and Webb, Matthew D.},
  title   = {Wild Bootstrap Inference for Wildly Different Cluster Sizes},
  journal = {Journal of Applied Econometrics},
  year    = {2017},
  volume  = {32},
  number  = {2},
  pages   = {233--254}
}
```

### Domain literature you should expand (occupational heat & injury)
Right now the paper mostly cites general climate-health/productivity work. A top journal referee will ask: what is known about heat and *injuries* (not just output/mortality), and what is known about heat standards specifically?

I recommend adding and engaging with:
- empirical evidence linking temperature/heat to workplace injury risk (often in public health / occupational medicine),
- studies of compliance/enforcement mechanisms in state-plan OSHA settings,
- any prior evaluations of California’s heat standard (even descriptive) beyond Tustin et al. (2018).

(If you want, I can propose a targeted reading list once you specify whether you can access workers’ comp microdata, OSHA severe injury reports, or establishment-level SOII microdata.)

### Contribution positioning
The claim “first causal estimates” (Abstract; Intro) is risky unless you can confidently rule out related quasi-experimental work using workers’ comp claims, hospitalizations, or OSHA enforcement variation. At minimum, soften to “to my knowledge” and demonstrate a systematic search.

---

# 5. WRITING QUALITY (CRITICAL)

### Strengths
- The introduction is readable, policy-motivated, and clearly frames OSHA’s 2024 proposal (Section 1).
- The econometric discussion is broadly competent and uses the right contemporary vocabulary (Section 2.3; Section 5).

### Weaknesses (important for top journals)
1. **Internal contradictions break narrative trust.** The CA/MD timing contradictions and the AZ error (Table 4) will cause referees to doubt the entire pipeline.
2. **Over-claiming relative to design maturity.** The policy extrapolation in Section 8 assumes the estimate is stable and externally valid; the current design does not yet warrant that.
3. **Insufficient intuition for magnitudes and units.**
   - You should clarify the unit scaling of SOII rates (SOII commonly reports incidence per 100 FTE-equivalent workers; you use per 10,000 FTE). This is easy to misread and needs explicit conversion and rationale.

### Tables/Figures as communication devices
- Tables are mostly interpretable, but you need more self-contained notes: data source, weighting (employment-weighted?), handling of suppressed cells, and exact industry aggregation.
- Figure 2’s event-time horizon is extremely short given what readers expect when you cite dynamic DiD/event-study methods. If that short horizon is forced by the data, you should say so explicitly and adjust expectations.

---

# 6. CONSTRUCTIVE SUGGESTIONS (to make it publishable)

## A. Fix the policy/sample design first (non-negotiable)
1. **Align the sample window with treatment timing.**
   - Either extend outcomes through **2024 (and ideally 2025)** to include Maryland post-treatment, or drop Maryland from the treated cohort list and treat it as not-yet-treated only.
2. **Resolve California identification.**
   - Option 1 (preferred): extend the panel back far enough to include **pre-2005** outcomes and show CA-specific event study.
   - Option 2: drop CA from the main DiD and present CA as a separate case study (synthetic control / interrupted time series).
   - Option 3: restrict the main design to the “recent adopter era” (2022–2024) and clearly label the estimand as short-run effects.

## B. Use industry-by-state variation (sharper design)
- Construct a **state × industry × year** panel for multiple outdoor industries.
- Exploit Colorado’s agriculture-only rule as a difference-in-difference-in-differences:
  - agriculture in CO should respond more than construction in CO, relative to the same industry contrast in control states.
- Similarly, Minnesota’s indoor-only rule can serve as a falsification test for *outdoor* outcomes.

## C. Directly link effects to realized heat exposure (mechanism + identification)
A persuasive design in this context is:
- \( \text{Injuries}_{s,t} = \alpha_s + \lambda_t + \beta \, (\text{Standard}_{s,t} \times \text{HotDays}_{s,t}) + \gamma \text{HotDays}_{s,t} + \dots \)
This makes the policy effect “turn on” when heat risk is actually present and mitigates confounding from differential warming trends.

## D. Strengthen inference
Given few treated cohorts:
- Implement **Conley–Taber** inference or **randomization inference** over adoption timing.
- Report wild cluster bootstrap p-values as a robustness check.
- Report sensitivity (HonestDiD) to modest pretrend violations.

## E. Outcome validation
SOII has known underreporting and sampling variability:
- Discuss measurement error explicitly and, if possible, validate with alternative data:
  - workers’ compensation claims (ideal),
  - OSHA severe injury reports (post-2015),
  - emergency department/hospital discharge data for heat illness (if linkable geographically/seasonally),
  - CFOI fatalities (for heat-related deaths, though small counts).

## F. Expand the set of “outdoor” industries
Agriculture + construction is a start, but outdoor exposure is substantial in:
- transportation/warehousing (some occupations),
- utilities,
- mining/oil & gas,
- landscaping/services to buildings,
- certain public-sector occupations (if data allow).
Even if SOII limits you, address external validity explicitly.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important policy question with clear relevance to imminent federal regulation.
- Uses modern DiD estimators rather than relying purely on TWFE.
- Attempts placebo outcomes and COVID sensitivity.

### Critical weaknesses
- **Design incoherence**: treatment timing vs sample window (MD), early-treated cohort without pre (CA), confusion about inclusion/exclusion (CO), and outright errors in heterogeneity (AZ; “bottom tercile hot”).
- **Thin identifying variation** in the stated 2010–2023 window: the effective post-treatment information is very limited, so strong claims and national extrapolation are not yet warranted.
- **Inference not fully credible** given few treated cohorts; needs specialized inference and/or stronger design leverage (industry-level / exposure-interaction).

### What would change my view
If you (i) align the panel with adoption timing, (ii) deal transparently with CA (either add pre-2005 data or remove from main DiD), (iii) exploit industry scope differences (CO, MN) rather than excluding them, and (iv) tie treatment effects to realized heat exposure with stronger inference, this could become a credible AEJ:EP paper and potentially a strong general-interest field piece.

DECISION: REJECT AND RESUBMIT